

Pierre Laurent-Puig

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1665250/publications.pdf>

Version: 2024-02-01

420
papers

53,827
citations

2669

95
h-index

1456

220
g-index

488
all docs

488
docs citations

488
times ranked

51494
citing authors

#	ARTICLE	IF	CITATIONS
1	Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. <i>Nature</i> , 2001, 411, 599-603.	13.7	5,088
2	The consensus molecular subtypes of colorectal cancer. <i>Nature Medicine</i> , 2015, 21, 1350-1356.	15.2	3,596
3	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016, 27, 1386-1422.	0.6	2,545
4	KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer. <i>Cancer Research</i> , 2006, 66, 3992-3995.	0.4	2,116
5	Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. <i>Genome Biology</i> , 2016, 17, 218.	3.8	1,980
6	Tumor Microsatellite-Instability Status as a Predictor of Benefit from Fluorouracil-Based Adjuvant Chemotherapy for Colon Cancer. <i>New England Journal of Medicine</i> , 2003, 349, 247-257.	13.9	1,962
7	Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. <i>Lancet Oncology</i> , 2010, 11, 753-762.	5.1	1,915
8	KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2008, 26, 374-379.	0.8	1,398
9	Gene Expression Classification of Colon Cancer into Molecular Subtypes: Characterization, Validation, and Prognostic Value. <i>PLoS Medicine</i> , 2013, 10, e1001453.	3.9	1,064
10	Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. <i>Hepatology</i> , 2007, 45, 42-52.	3.6	1,034
11	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	9.4	960
12	Mapping of a susceptibility locus for Crohn's disease on chromosome 16. <i>Nature</i> , 1996, 379, 821-823.	13.7	906
13	Integrative Analyses of Colorectal Cancer Show Immunoscore Is a Stronger Predictor of Patient Survival Than Microsatellite Instability. <i>Immunity</i> , 2016, 44, 698-711.	6.6	814
14	Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study. <i>British Journal of Cancer</i> , 2001, 85, 692-696.	2.9	790
15	Genotype-phenotype correlation in hepatocellular adenoma: New classification and relationship with HCC. <i>Hepatology</i> , 2006, 43, 515-524.	3.6	733
16	Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5924-5930.	0.8	645
17	Alleles of the APC gene: An attenuated form of familial polyposis. <i>Cell</i> , 1993, 75, 951-957.	13.5	611
18	Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2020, 31, 1291-1305.	0.6	591

#	ARTICLE	IF	CITATIONS
19	Genetic alterations associated with hepatocellular carcinomas define distinct pathways of hepatocarcinogenesis. <i>Gastroenterology</i> , 2001, 120, 1763-1773.	0.6	539
20	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	9.4	493
21	Quantitative and sensitive detection of rare mutations using droplet-based microfluidics. <i>Lab on A Chip</i> , 2011, 11, 2156.	3.1	461
22	Immune and Stromal Classification of Colorectal Cancer Is Associated with Molecular Subtypes and Relevant for Precision Immunotherapy. <i>Clinical Cancer Research</i> , 2016, 22, 4057-4066.	3.2	433
23	Multiplex Picodroplet Digital PCR to Detect KRAS Mutations in Circulating DNA from the Plasma of Colorectal Cancer Patients. <i>Clinical Chemistry</i> , 2013, 59, 1722-1731.	1.5	429
24	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	9.4	374
25	Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. <i>Science</i> , 2015, 350, 972-978.	6.0	367
26	Association of p53 mutations with short survival in colorectal cancer. <i>Gastroenterology</i> , 1994, 106, 42-48.	0.6	348
27	Stratification of Pancreatic Ductal Adenocarcinomas Based on Tumor and Microenvironment Features. <i>Gastroenterology</i> , 2018, 155, 1999-2013.e3.	0.6	347
28	Cytochrome P450 2C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. <i>Blood</i> , 2005, 106, 135-140.	0.6	335
29	Bi-allelic inactivation of TCF1 in hepatic adenomas. <i>Nature Genetics</i> , 2002, 32, 312-315.	9.4	333
30	Amphiregulin and Epiregulin mRNA Expression in Primary Tumors Predicts Outcome in Metastatic Colorectal Cancer Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2009, 27, 5068-5074.	0.8	325
31	Restriction of ocular fundus lesions to a specific subgroup of APC mutations in adenomatous polyposis coli patients. <i>Cell</i> , 1993, 75, 959-968.	13.5	307
32	Genetics of hepatocellular tumors. <i>Oncogene</i> , 2006, 25, 3778-3786.	2.6	304
33	A Hepatocellular Carcinoma 5-Gene Score Associated With Survival of Patients After Liver Resection. <i>Gastroenterology</i> , 2013, 145, 176-187.	0.6	302
34	Mutations in the RAS-RAF-MAPK, PI(3)K (phosphatidylinositol 3-OH kinase) signaling network correlate with poor survival in a population-based series of colon cancers. <i>International Journal of Cancer</i> , 2008, 122, 2255-2259.	2.3	273
35	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	9.4	265
36	Association of the Multidrug Resistance-1 Gene Single-Nucleotide Polymorphisms with the Tacrolimus Dose Requirements in Renal Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 1889-1896.	3.0	257

#	ARTICLE	IF	CITATIONS
37	Crypt-restricted proliferation and commitment to the Paneth cell lineage following Apc loss in the mouse intestine. <i>Development (Cambridge)</i> , 2005, 132, 1443-1451.	1.2	257
38	<i>TP53</i> , <i>STK11</i> , and <i>EGFR</i> Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5710-5723.	3.2	257
39	Detection of free-circulating tumor-associated DNA in plasma of colorectal cancer patients and its association with prognosis. <i>International Journal of Cancer</i> , 2002, 100, 542-548.	2.3	252
40	Hypermethylator Phenotype in Sporadic Colon Cancer: Study on a Population-Based Series of 582 Cases. <i>Cancer Research</i> , 2008, 68, 8541-8546.	0.4	247
41	Small bowel adenocarcinoma: Epidemiology, risk factors, diagnosis and treatment. <i>Digestive and Liver Disease</i> , 2014, 46, 97-104.	0.4	245
42	Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 862-873.	5.1	239
43	Thymidylate Synthase Gene Polymorphism Predicts Toxicity in Colorectal Cancer Patients Receiving 5-Fluorouracil-based Chemotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 5880-5888.	3.2	228
44	Genetic Markers of Toxicity From Capecitabine and Other Fluorouracil-Based Regimens: Investigation in the QUASAR2 Study, Systematic Review, and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2014, 32, 1031-1039.	0.8	216
45	Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. <i>Immunity</i> , 2022, 55, 527-541.e5.	6.6	215
46	Alternative genetic pathways in colorectal carcinogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 12122-12127.	3.3	209
47	Clinical, Morphologic, and Molecular Features Defining So-Called Telangiectatic Focal Nodular Hyperplasias of the Liver. <i>Gastroenterology</i> , 2005, 128, 1211-1218.	0.6	207
48	Plasma Circulating Tumor DNA in Pancreatic Cancer Patients Is a Prognostic Marker. <i>Clinical Cancer Research</i> , 2017, 23, 116-123.	3.2	205
49	Functional Variants at the 11q13 Risk Locus for Breast Cancer Regulate Cyclin D1 Expression through Long-Range Enhancers. <i>American Journal of Human Genetics</i> , 2013, 92, 489-503.	2.6	201
50	Glutathione S-Transferase P1 Polymorphism (Ile105Val) Predicts Cumulative Neuropathy in Patients Receiving Oxaliplatin-Based Chemotherapy. <i>Clinical Cancer Research</i> , 2006, 12, 3050-3056.	3.2	196
51	Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study). <i>Clinical Cancer Research</i> , 2017, 23, 5416-5425.	3.2	189
52	Survival and acquired genetic alterations in colorectal cancer. <i>Gastroenterology</i> , 1992, 102, 1136-1141.	0.6	182
53	p53 Alterations Predict Tumor Response to Neoadjuvant Chemotherapy in Head and Neck Squamous Cell Carcinoma: A Prospective Series. <i>Journal of Clinical Oncology</i> , 2000, 18, 1465-1473.	0.8	178
54	Prognostic Value of Tumoral Thymidylate Synthase and p53 in Metastatic Colorectal Cancer Patients Receiving Fluorouracil-Based Chemotherapy: Phenotypic and Genotypic Analyses. <i>Journal of Clinical Oncology</i> , 2002, 20, 2832-2843.	0.8	177

#	ARTICLE	IF	CITATIONS
55	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 422-433.	2.3	171
56	Droplet-based digital PCR and next generation sequencing for monitoring circulating tumor DNA: a cancer diagnostic perspective. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 7-17.	1.5	165
57	TP53 gene mutations and p53 protein immunoreactivity in malignant and premalignant Barrett's esophagus. <i>Gastroenterology</i> , 1994, 107, 1012-1018.	0.6	162
58	Immune Contexture, Immunoscore, and Malignant Cell Molecular Subgroups for Prognostic and Theranostic Classifications of Cancers. <i>Advances in Immunology</i> , 2016, 130, 95-190.	1.1	160
59	KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy. <i>International Journal of Cancer</i> , 2013, 133, 1259-1265.	2.3	154
60	Targeting c-MET in gastrointestinal tumours: rationale, opportunities and challenges. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 562-576.	12.5	150
61	Hepatitis C virus genotyping by means of 5 ^{â€²} -UR/core line probe assays and molecular analysis of untypeable samples. <i>Virus Research</i> , 1995, 38, 137-157.	1.1	149
62	Beta-catenin mutations in hepatocellular carcinoma correlate with a low rate of loss of heterozygosity. <i>Oncogene</i> , 1999, 18, 4044-4046.	2.6	149
63	K-Ras Mutations and Treatment Outcome in Colorectal Cancer Patients Receiving Exclusive Fluoropyrimidine Therapy. <i>Clinical Cancer Research</i> , 2008, 14, 4830-4835.	3.2	146
64	Pharmacogenetic Assessment of Toxicity and Outcome in Patients With Metastatic Colorectal Cancer Treated With LV5FU2, FOLFOX, and FOLFIRI: FFCD 2000-05. <i>Journal of Clinical Oncology</i> , 2010, 28, 2556-2564.	0.8	146
65	Influence of epidermal growth factor receptor (EGFR), p53 and intrinsic MAP kinase pathway status of tumour cells on the antiproliferative effect of ZD1839 (Iressa TM). <i>British Journal of Cancer</i> , 2002, 86, 1518-1523.	2.9	143
66	Increased p53 protein content of colorectal tumours correlates with poor survival. <i>British Journal of Cancer</i> , 1992, 66, 758-764.	2.9	141
67	Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. <i>Cancer Research</i> , 1993, 53, 5872-6.	0.4	141
68	Clinical Relevance of KRAS-Mutated Subclones Detected with Picodroplet Digital PCR in Advanced Colorectal Cancer Treated with Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2015, 21, 1087-1097.	3.2	137
69	RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGE0 RASANC prospective multicenter study. <i>Annals of Oncology</i> , 2018, 29, 1211-1219.	0.6	136
70	Clinical Value of Mitochondrial Mutations in Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 3517-3525.	0.8	133
71	CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. <i>Journal of Medical Genetics</i> , 2013, 50, 486-489.	1.5	131
72	Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas. <i>Journal of Pathology</i> , 2017, 242, 10-15.	2.1	130

#	ARTICLE	IF	CITATIONS
73	Consequences of Genetic Polymorphisms for Sirolimus Requirements After Renal Transplant in Patients on Primary Sirolimus Therapy. <i>American Journal of Transplantation</i> , 2005, 5, 595-603.	2.6	129
74	Screening for germ-line mutations in theNF2 Gene. <i>Genes Chromosomes and Cancer</i> , 1995, 12, 117-127.	1.5	128
75	UGT1A1 Polymorphism Can Predict Hematologic Toxicity in Patients Treated with Irinotecan. <i>Clinical Cancer Research</i> , 2007, 13, 3269-3275.	3.2	128
76	Chromoendoscopic Colonoscopy for Detecting Preneoplastic Lesions in Hereditary Nonpolyposis Colorectal Cancer Syndrome. <i>Clinical Gastroenterology and Hepatology</i> , 2005, 3, 897-902.	2.4	127
77	Complex interplay between β -catenin signalling and Notch effectors in intestinal tumorigenesis. <i>Gut</i> , 2011, 60, 166-176.	6.1	127
78	Clinical and molecular analysis of combined hepatocellular-cholangiocarcinomas. <i>Journal of Hepatology</i> , 2004, 41, 292-298.	1.8	126
79	Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA. <i>British Journal of Cancer</i> , 2002, 87, 551-554.	2.9	125
80	Prognostic Effect of <i>BRAF</i> and <i>KRAS</i> Mutations in Patients With Stage III Colon Cancer Treated With Leucovorin, Fluorouracil, and Oxaliplatin With or Without Cetuximab. <i>JAMA Oncology</i> , 2016, 2, 643.	3.4	125
81	Identification of the IFITM Family as a New Molecular Marker in Human Colorectal Tumors. <i>Cancer Research</i> , 2006, 66, 1949-1955.	0.4	120
82	Mutations and Response to Epidermal Growth Factor Receptor Inhibitors: Fig. 1.. <i>Clinical Cancer Research</i> , 2009, 15, 1133-1139.	3.2	120
83	APC gene: database of germline and somatic mutations in human tumors and cell lines. <i>Nucleic Acids Research</i> , 1998, 26, 269-270.	6.5	119
84	Sporadic Early-Onset Colorectal Cancer Is a Specific Sub-Type of Cancer: A Morphological, Molecular and Genetics Study. <i>PLoS ONE</i> , 2014, 9, e103159.	1.1	119
85	Identification in Daily Practice of Patients With Lynch Syndrome (Hereditary Nonpolyposis Colorectal) Tj ETQq1 1 0.784314 rgBT /Over <i>Journal of Gastroenterology</i> , 2008, 103, 2825-2835.	0.2	118
86	A Study of Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker. <i>Clinical Chemistry</i> , 2016, 62, 1129-1139.	1.5	111
87	Mutational analysis of thePTEN gene in gliomas: Molecular and pathological correlations. , 1999, 84, 150-154.		110
88	Germline hepatocyte nuclear factor 1 α and 1 β mutations in renal cell carcinomas. <i>Human Molecular Genetics</i> , 2005, 14, 603-614.	1.4	109
89	Subgroups and prognostication in stage III colon cancer: future perspectives for adjuvant therapy. <i>Annals of Oncology</i> , 2017, 28, 958-968.	0.6	107
90	Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. <i>Experimental and Molecular Pathology</i> , 2012, 92, 275-280.	0.9	106

#	ARTICLE	IF	CITATIONS
91	Butyrate elicits a metabolic switch in human colon cancer cells by targeting the pyruvate dehydrogenase complex. <i>International Journal of Cancer</i> , 2011, 128, 2591-2601.	2.3	105
92	Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy. <i>JAMA Oncology</i> , 2018, 4, 379.	3.4	104
93	Germ-line mutations in the first 14 exons of the adenomatous polyposis coli (APC) gene. <i>American Journal of Human Genetics</i> , 1993, 52, 273-9.	2.6	103
94	BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. <i>American Journal of Human Genetics</i> , 1997, 60, 1021-30.	2.6	103
95	Association between Parkinson's disease and the <i>HLA-DRB1</i> locus. <i>Movement Disorders</i> , 2012, 27, 1104-1110.	2.2	102
96	Oncogenic mutations as predictive factors in colorectal cancer. <i>Oncogene</i> , 2010, 29, 3033-3043.	2.6	98
97	Fine-Scale Mapping of the FGFR2 Breast Cancer Risk Locus: Putative Functional Variants Differentially Bind FOXA1 and E2F1. <i>American Journal of Human Genetics</i> , 2013, 93, 1046-1060.	2.6	98
98	Multiplex Picoliter-Droplet Digital PCR for Quantitative Assessment of DNA Integrity in Clinical Samples. <i>Clinical Chemistry</i> , 2013, 59, 815-823.	1.5	98
99	Hsa-miR-31-3p Expression Is Linked to Progression-free Survival in Patients with KRAS Wild-type Metastatic Colorectal Cancer Treated with Anti-EGFR Therapy. <i>Clinical Cancer Research</i> , 2014, 20, 3338-3347.	3.2	98
100	Chronic endogenous hypergastrinemia in humans: Evidence for a mitogenic effect on the colonic mucosa. <i>Gastroenterology</i> , 1993, 105, 22-30.	0.6	96
101	A genetic study of the role of the Wnt/ β -catenin signalling in Paneth cell differentiation. <i>Developmental Biology</i> , 2008, 324, 288-296.	0.9	96
102	Small bowel adenocarcinoma phenotyping, a clinicobiological prognostic study. <i>British Journal of Cancer</i> , 2013, 109, 3057-3066.	2.9	94
103	Detecting biomarkers with microdroplet technology. <i>Trends in Molecular Medicine</i> , 2012, 18, 405-416.	3.5	93
104	Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset. <i>Annals of Oncology</i> , 2014, 25, 2378-2385.	0.6	93
105	Highly Sensitive Quantification of Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Sheds Light on its Potential Clinical Value. <i>Clinical Infectious Diseases</i> , 2021, 73, e2890-e2897.	2.9	92
106	Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms: relationships with 5-fluorouracil sensitivity. <i>British Journal of Cancer</i> , 2004, 90, 526-534.	2.9	91
107	Germline mutation profile of the VHL gene in von Hippel-Lindau disease and in sporadic hemangioblastoma. , 1998, 12, 424-430.		89
108	The Balance Between Cytotoxic T-cell Lymphocytes and Immune Checkpoint Expression in the Prognosis of Colon Tumors. <i>Journal of the National Cancer Institute</i> , 2018, 110, 68-77.	3.0	89

#	ARTICLE	IF	CITATIONS
109	Epidermal Growth Factor Receptor Mutation in Lung Cancer are Linked to Bronchioloalveolar Differentiation. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1309-1315.	2.1	86
110	The prevalence of colonic polyps in acromegaly: a colonoscopic and pathological study in 103 patients. <i>Journal of Clinical Endocrinology and Metabolism</i> , 1995, 80, 3223-3226.	1.8	86
111	Simultaneous monitoring of P53 protein and dna content of colorectal adenocarcinomas by flow cytometry. <i>International Journal of Cancer</i> , 1990, 45, 450-456.	2.3	83
112	Polymerase chain reaction assay for the detection of <i>Helicobacter pylori</i> in gastric biopsy specimens: comparison with culture, rapid urease test, and histopathological tests.. <i>Gut</i> , 1994, 35, 905-908.	6.1	83
113	External Quality Assessment for <i>KRAS</i> Testing Is Needed: Setup of a European Program and Report of the First Joined Regional Quality Assessment Rounds. <i>Oncologist</i> , 2011, 16, 467-478.	1.9	83
114	Systemic treatment of pancreatic cancer revisited. <i>Seminars in Oncology</i> , 2019, 46, 28-38.	0.8	81
115	The New Histologic Classification of Lung Primary Adenocarcinoma Subtypes Is a Reliable Prognostic Marker and Identifies Tumors With Different Mutation Status. <i>Chest</i> , 2014, 146, 633-643.	0.4	80
116	Is the multiple endocrine neoplasia type 1 gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome?. <i>Gastroenterology</i> , 1993, 105, 579-582.	0.6	79
117	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma. <i>European Journal of Cancer</i> , 2014, 50, 1740-1746.	1.3	79
118	Multiplex Detection of Rare Mutations by Picoliter Droplet Based Digital PCR: Sensitivity and Specificity Considerations. <i>PLoS ONE</i> , 2016, 11, e0159094.	1.1	78
119	Panitumumab combined with irinotecan for patients with <i>KRAS</i> wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study. <i>Annals of Oncology</i> , 2013, 24, 412-419.	0.6	76
120	Base-Position Error Rate Analysis of Next-Generation Sequencing Applied to Circulating Tumor DNA in Non-Small Cell Lung Cancer: A Prospective Study. <i>PLoS Medicine</i> , 2016, 13, e1002199.	3.9	76
121	The Soluble $\hat{\pm}$ Chain of Interleukin-15 Receptor: A Proinflammatory Molecule Associated with Tumor Progression in Head and Neck Cancer. <i>Cancer Research</i> , 2008, 68, 3907-3914.	0.4	75
122	Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours. <i>Annals of Oncology</i> , 2013, 24, 2624-2629.	0.6	75
123	TP53 and head and neck neoplasms. <i>Human Mutation</i> , 2003, 21, 252-257.	1.1	72
124	Molecular targeted therapy of <i>BRAF</i> -mutant colorectal cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2019, 11, 175883591985649.	1.4	72
125	Breast cancer risk, nightwork, and circadian clock gene polymorphisms. <i>Endocrine-Related Cancer</i> , 2014, 21, 629-638.	1.6	71
126	Serological determination of hepatitis C virus genotype: comparison with a standardized genotyping assay. <i>Journal of Clinical Microbiology</i> , 1997, 35, 1734-1739.	1.8	71

#	ARTICLE	IF	CITATIONS
127	Recurrent inactivating mutations of <i>ARID2</i> in non-small cell lung carcinoma. <i>International Journal of Cancer</i> , 2013, 132, 2217-2221.	2.3	70
128	Evidence of linkage of the inflammatory bowel disease susceptibility locus on chromosome 16 (IBD1) to ulcerative colitis. <i>Journal of Medical Genetics</i> , 1998, 35, 218-221.	1.5	68
129	Sensitivity to CPT-11 of xenografted human colorectal cancers as a function of microsatellite instability and p53 status. <i>British Journal of Cancer</i> , 2000, 82, 913-923.	2.9	68
130	MicroRNA and colorectal cancer. <i>Digestive and Liver Disease</i> , 2012, 44, 195-200.	0.4	68
131	Analysis of Base-Position Error Rate of Next-Generation Sequencing to Detect Tumor Mutations in Circulating DNA. <i>Clinical Chemistry</i> , 2016, 62, 1492-1503.	1.5	68
132	Different prognostic impact of <i>STK11</i> mutations in non-squamous non-small-cell lung cancer. <i>Oncotarget</i> , 2017, 8, 23831-23840.	0.8	67
133	Polymorphisms and probable lack of mutation in the WAF1-CIP1 gene in colorectal cancer. <i>Oncogene</i> , 1995, 10, 599-601.	2.6	66
134	Specific association between alcohol intake, high grade of differentiation and 4q34-q35 deletions in hepatocellular carcinomas identified by high resolution allelotyping. <i>Oncogene</i> , 2002, 21, 1225-1232.	2.6	65
135	HPV circulating tumoral DNA quantification by droplet-based digital PCR: A promising predictive and prognostic biomarker for HPV-associated oropharyngeal cancers. <i>International Journal of Cancer</i> , 2020, 147, 1222-1227.	2.3	65
136	Human fibulin-4: analysis of its biosynthetic processing and mRNA expression in normal and tumour tissues. <i>FEBS Letters</i> , 2001, 489, 59-66.	1.3	62
137	Association of CYP1B1 Germ Line Mutations with Hepatocyte Nuclear Factor 1 α Mutated Hepatocellular Adenoma. <i>Cancer Research</i> , 2007, 67, 2611-2616.	0.4	62
138	<i>DPYD</i> Genotyping to Predict Adverse Events Following Treatment With Fluorouracil-Based Adjuvant Chemotherapy in Patients With Stage III Colon Cancer. <i>JAMA Oncology</i> , 2016, 2, 655.	3.4	62
139	Detection of plasma tumor DNA in head and neck squamous cell carcinoma by microsatellite typing and p53 mutation analysis. <i>Cancer Research</i> , 2000, 60, 707-11.	0.4	62
140	Association of ki-ras mutation with differentiation and tumor-formation pathways in colorectal carcinoma. <i>International Journal of Cancer</i> , 1991, 49, 220-223.	2.3	61
141	Polymorphisms of human aryl hydrocarbon receptor (AhR) gene in a French population: relationship with CYP1A1 inducibility and lung cancer. <i>Carcinogenesis</i> , 2001, 22, 1819-1824.	1.3	61
142	TWIST1 a New Determinant of Epithelial to Mesenchymal Transition in EGFR Mutated Lung Adenocarcinoma. <i>PLoS ONE</i> , 2012, 7, e29954.	1.1	61
143	Histologic subtypes, immunohistochemistry, FISH or molecular screening for the accurate diagnosis of ALK-rearrangement in lung cancer: A comprehensive study of Caucasian non-smokers. <i>Lung Cancer</i> , 2012, 76, 309-315.	0.9	59
144	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. <i>Biomolecules</i> , 2020, 10, 1061.	1.8	59

#	ARTICLE	IF	CITATIONS
145	Variation in the risk of colorectal cancer in families with Lynch syndrome: a retrospective cohort study. <i>Lancet Oncology</i> , 2021, 22, 1014-1022.	5.1	58
146	Spectrum of <i>HNFI1A</i> Somatic Mutations in Hepatocellular Adenoma Differs From That in Patients With <i>MODY3</i> and Suggests Genotoxic Damage. <i>Diabetes</i> , 2010, 59, 1836-1844.	0.3	57
147	Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma. <i>British Journal of Cancer</i> , 2006, 94, 692-697.	2.9	56
148	Genetic polymorphisms of <i>MMP1</i> , <i>MMP3</i> and <i>MMP7</i> gene promoter and risk of colorectal adenoma. <i>BMC Cancer</i> , 2006, 6, 270.	1.1	56
149	Epithelial-to-Mesenchymal Transition and MicroRNAs in Lung Cancer. <i>Cancers</i> , 2017, 9, 101.	1.7	56
150	Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.. <i>Gut</i> , 1995, 36, 455-458.	6.1	55
151	A <i>let-7</i> microRNA-Binding Site Polymorphism in <i>KRAS</i> Predicts Improved Outcome in Patients with Metastatic Colorectal Cancer Treated with Salvage Cetuximab/Panitumumab Monotherapy. <i>Clinical Cancer Research</i> , 2014, 20, 4499-4510.	3.2	55
152	Association of Prognostic Value of Primary Tumor Location in Stage III Colon Cancer With <i>RAS</i> and <i>BRAF</i> Mutational Status. <i>JAMA Oncology</i> , 2018, 4, e173695.	3.4	55
153	Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors. <i>Journal of Thoracic Oncology</i> , 2019, 14, 844-856.	0.5	55
154	Efficient screening of p53 mutations by denaturing gradient gel electrophoresis in colorectal tumors. <i>Oncogene</i> , 1993, 8, 2213-20.	2.6	55
155	Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients. <i>European Journal of Clinical Pharmacology</i> , 2011, 67, 253-260.	0.8	54
156	Current and Future Molecular Testing in NSCLC, What Can We Expect from New Sequencing Technologies?. <i>Journal of Clinical Medicine</i> , 2018, 7, 144.	1.0	54
157	Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma. <i>Hepatology</i> , 1992, 16, 1171-1175.	3.6	53
158	Identification of molecular pathways involved in oxaliplatin-associated sinusoidal dilatation. <i>Journal of Hepatology</i> , 2012, 56, 869-876.	1.8	53
159	Microsatellite instability and intratumoural heterogeneity in 100 right-sided sporadic colon carcinomas. <i>British Journal of Cancer</i> , 2002, 87, 400-404.	2.9	52
160	Circulating free tumor DNA and colorectal cancer. <i>Gastroenterologie Clinique Et Biologique</i> , 2010, 34, 662-681.	0.9	51
161	Prognostic and theranostic impact of molecular subtypes and immune classifications in renal cell cancer (RCC) and colorectal cancer (CRC). <i>Oncolimmunology</i> , 2015, 4, e1049804.	2.1	51
162	Molecular markers and prediction of response to immunotherapy in non-small cell lung cancer, an update. <i>Journal of Thoracic Disease</i> , 2019, 11, S25-S36.	0.6	51

#	ARTICLE	IF	CITATIONS
163	Frequent allelic loss at chromosome 3p distinct from genetic alterations of the 8-oxoguanine DNA glycosylase 1 gene in head and neck cancer. <i>Molecular Carcinogenesis</i> , 1999, 26, 254-260.	1.3	50
164	p16INK4A inactivation mechanisms in non-small-cell lung cancer patients occupationally exposed to asbestos. <i>Lung Cancer</i> , 2010, 67, 23-30.	0.9	50
165	Glutathione-associated enzymes in head and neck squamous cell carcinoma and response to cisplatin-based neoadjuvant chemotherapy. <i>International Journal of Cancer</i> , 2001, 93, 725-730.	2.3	49
166	Pharmacogenetics of acenocoumarol pharmacodynamics. <i>Clinical Pharmacology and Therapeutics</i> , 2004, 75, 403-414.	2.3	49
167	MicroRNA Related Polymorphisms and Breast Cancer Risk. <i>PLoS ONE</i> , 2014, 9, e109973.	1.1	49
168	Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. <i>British Journal of Cancer</i> , 2014, 110, 1148-1154.	2.9	49
169	Development of a semi-conductor sequencing-based panel for genotyping of colon and lung cancer by the Onconetwork consortium. <i>BMC Cancer</i> , 2015, 15, 26.	1.1	49
170	Prognostic value of p53 mutations in rectal carcinoma. <i>International Journal of Cancer</i> , 2002, 100, 131-135.	2.3	48
171	Impact of Chromoscopy on Adenoma Detection in Patients With Lynch Syndrome: A Prospective, Multicenter, Blinded, Tandem Colonoscopy Study. <i>American Journal of Gastroenterology</i> , 2015, 110, 288-298.	0.2	48
172	Intratumoral Immune Cell Densities Are Associated with Lung Adenocarcinoma Gene Alterations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016, 194, 1403-1412.	2.5	48
173	The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer. <i>Drugs</i> , 2019, 79, 1375-1394.	4.9	48
174	Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer. <i>International Journal of Cancer</i> , 2010, 127, 1321-1331.	2.3	45
175	Influence of cirrhosis on lamotrigine pharmacokinetics. <i>British Journal of Clinical Pharmacology</i> , 2001, 51, 410-414.	1.1	43
176	3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer. <i>European Journal of Cancer</i> , 2017, 79, 41-49.	1.3	43
177	CDX2 prognostic value in stage II/III resected colon cancer is related to CMS classification. <i>Annals of Oncology</i> , 2017, 28, 1032-1035.	0.6	43
178	Linkage analyses of chromosome 6 loci, including HLA, in familial aggregations of Crohn disease. <i>American Journal of Medical Genetics Part A</i> , 1994, 52, 207-213.	2.4	42
179	Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from patients with colorectal cancer: Relationship with response to 5-fluorouracil and survival. <i>International Journal of Cancer</i> , 2001, 95, 162-167.	2.3	42
180	Prognostic Value and Relation with Adjuvant Treatment Duration of ctDNA in Stage III Colon Cancer: Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5638-5646.	3.2	42

#	ARTICLE	IF	CITATIONS
181	Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. <i>Oncotarget</i> , 2017, 8, 93856-93866.	0.8	42
182	Prognostic significance of MMP-1 and MMP-3 functional promoter polymorphisms in colorectal cancer. <i>Clinical Cancer Research</i> , 2005, 11, 594-9.	3.2	42
183	Diagnosis, prognosis and treatment of patients with gastrointestinal stromal tumour (GIST) and germline mutation of KIT exon 13. <i>European Journal of Cancer</i> , 2013, 49, 2531-2541.	1.3	41
184	Characterization of a frequent polymorphism in the coding sequence of the Tp53 gene in colonic cancer patients and a control population. <i>Human Genetics</i> , 1991, 86, 369-70.	1.8	40
185	BCL-2 system analysis identifies high-risk colorectal cancer patients. <i>Gut</i> , 2017, 66, 2141-2148.	6.1	40
186	Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX. <i>European Journal of Cancer</i> , 2017, 82, 16-24.	1.3	40
187	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	1.5	39
188	Methylator phenotype in colorectal cancer: A prognostic factor or not?. <i>Critical Reviews in Oncology/Hematology</i> , 2016, 99, 74-80.	2.0	39
189	Mutation and Methylation Analysis of Circulating Tumor DNA Can Be Used for Follow-up of Metastatic Colorectal Cancer Patients. <i>Clinical Colorectal Cancer</i> , 2018, 17, e369-e379.	1.0	39
190	Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. <i>Scientific Reports</i> , 2019, 9, 16971.	1.6	39
191	Adjuvant FOLFOX +/â€ cetuximab in fullRAS andBRAF wildtype stage III colon cancer patients. <i>Annals of Oncology</i> , 2017, 28, 824-830.	0.6	38
192	Matrix Metalloproteinase 3 Polymorphism. <i>Clinical Cancer Research</i> , 2004, 10, 2594-2599.	3.2	36
193	Absence of mutation in the putative tumor-suppressor gene KLF6 in colorectal cancers. <i>Oncogene</i> , 2005, 24, 7253-7256.	2.6	36
194	Modeling RAS Phenotype in Colorectal Cancer Uncovers Novel Molecular Traits of RAS Dependency and Improves Prediction of Response to Targeted Agents in Patients. <i>Clinical Cancer Research</i> , 2014, 20, 265-272.	3.2	36
195	The effect of the UGT1A1*28 allele on survival after irinotecan-based chemotherapy: a collaborative meta-analysis. <i>Pharmacogenomics Journal</i> , 2014, 14, 424-431.	0.9	36
196	Angiogenin Mediates Cell-Autonomous Translational Control under Endoplasmic Reticulum Stress and Attenuates Kidney Injury. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 863-876.	3.0	36
197	Clinicopathologic Characteristics of Endometrial Cancer in Lynch Syndrome. <i>International Journal of Gynecological Cancer</i> , 2017, 27, 953-960.	1.2	36
198	Microsatellite analysis and response to chemotherapy in head-and-neck squamous-cell carcinoma. , 1999, 84, 410-415.		35

#	ARTICLE	IF	CITATIONS
199	Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. <i>Mutagenesis</i> , 2013, 28, 323-331.	1.0	35
200	Somatically acquired genetic alterations in flat colorectal neoplasias. , 1998, 77, 366-369.		34
201	Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities. <i>Annals of Oncology</i> , 2017, 28, 1597-1604.	0.6	34
202	Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019, 25, 134-141.	3.2	34
203	Colorectal Cancer Subtyping Consortium (CRCSC) identification of a consensus of molecular subtypes.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3511-3511.	0.8	34
204	Myeloperoxidase. <i>Pharmacogenetics and Genomics</i> , 2003, 13, 729-739.	5.7	33
205	Genetic diversity of hepatocellular carcinomas and its potential impact on targeted therapies. <i>Pharmacogenomics</i> , 2007, 8, 997-1003.	0.6	33
206	Advanced small bowel adenocarcinoma: Molecular characteristics and therapeutic perspectives. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2016, 40, 154-160.	0.7	33
207	BIABooster: Online DNA Concentration and Size Profiling with a Limit of Detection of 10 fg/µL and Application to High-Sensitivity Characterization of Circulating Cell-Free DNA. <i>Analytical Chemistry</i> , 2018, 90, 3766-3774.	3.2	33
208	<i>KRAS</i> Mutation Signature in Colorectal Tumors Significantly Overlaps With the Cetuximab Response Signature. <i>Journal of Clinical Oncology</i> , 2008, 26, 2228-2230.	0.8	32
209	Predictive value of KRAS mutations in chemoresistant CRC. <i>Nature Reviews Clinical Oncology</i> , 2009, 6, 306-307.	12.5	32
210	Prognostic influence of clinicopathologic features, DNA-ploidy, CD44H and p53 expression in a large series of resected hepatocellular carcinoma in france. , 1997, 74, 614-619.		31
211	Genome wide SNP comparative analysis between EGFR and KRAS mutated NSCLC and characterization of two models of oncogenic cooperation in non-small cell lung carcinoma. <i>BMC Medical Genomics</i> , 2008, 1, 25.	0.7	30
212	ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy. <i>Journal of Cancer</i> , 2014, 5, 425-432.	1.2	30
213	Validity of Targeted Next-Generation Sequencing in Routine Care for Identifying Clinically Relevant Molecular Profiles in Non-“Small-Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 550-564.	1.2	30
214	Molecular Tumor Boards: Ethical Issues in the New Era of Data Medicine. <i>Science and Engineering Ethics</i> , 2018, 24, 307-322.	1.7	29
215	Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy. <i>Oncolmmunology</i> , 2017, 6, e1286437.	2.1	28
216	A TLR3 Ligand Reestablishes Chemotherapeutic Responses in the Context of FPR1 Deficiency. <i>Cancer Discovery</i> , 2021, 11, 408-423.	7.7	28

#	ARTICLE	IF	CITATIONS
217	Single nucleotide polymorphisms in MMP1 and MMP3 gene promoters as risk factor in head and neck squamous cell carcinoma. <i>Anticancer Research</i> , 2004, 24, 2021-6.	0.5	28
218	Integrating Heterogeneous Biomedical Data for Cancer Research: the CARPEM infrastructure. <i>Applied Clinical Informatics</i> , 2016, 07, 260-274.	0.8	27
219	Enhanced detection of antibodies to hepatitis C virus by use of a third-generation recombinant immunoblot assay. <i>Journal of Medical Virology</i> , 1994, 43, 259-261.	2.5	26
220	Deletion mapping of the tumor suppressor locus involved in colorectal cancer on chromosome band 8p21. , 1999, 25, 147-153.		26
221	A Novel Extrinsic Pathway for the Unfolded Protein Response in the Kidney. <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 2670-2683.	3.0	26
222	Plasma clearance of <i>RAS</i> mutation under therapeutic pressure is a rare event in metastatic colorectal cancer. <i>International Journal of Cancer</i> , 2020, 147, 1185-1189.	2.3	26
223	A high hepatitis E virus seroprevalence among renal transplantation and haemophilia patient populations. <i>Journal of Hepatology</i> , 1996, 24, 122-123.	1.8	25
224	Cetuximab plus FOLFOX-4 for fully resected stage III colon carcinoma: scientific background and the ongoing PETACC-8 trial. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 183-189.	1.1	25
225	PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer. <i>Cancer Medicine</i> , 2015, 4, 371-382.	1.3	25
226	Diversity of genetic events associated with MLH1 promoter methylation in Lynch syndrome families with heritable constitutional epimutation. <i>Genetics in Medicine</i> , 2018, 20, 1589-1599.	1.1	25
227	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4768-4780.	3.2	25
228	Hysteroscopic findings in women at risk of HNPCC. Results of a prospective observational study. <i>Familial Cancer</i> , 2007, 6, 295-299.	0.9	24
229	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019, 46, 94-104.	2.7	24
230	Clinical utility of colon cancer molecular subtypes: Validation of two main colorectal molecular classifications on the PETACC-8 phase III trial cohort.. <i>Journal of Clinical Oncology</i> , 2017, 35, 3509-3509.	0.8	24
231	Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS). <i>European Journal of Cancer</i> , 2021, 159, 24-33.	1.3	24
232	Qualitative gene profiling: a novel tool in genomics and in pharmacogenomics that deciphers messenger RNA isoforms diversity. <i>Pharmacogenomics</i> , 2000, 1, 187-197.	0.6	23
233	Frequent mutations of hepatocyte nuclear factor 1 in colorectal cancer with microsatellite instability. <i>Gastroenterology</i> , 2003, 124, 1311-1314.	0.6	23
234	Performance and Cost Efficiency of KRAS Mutation Testing for Metastatic Colorectal Cancer in Routine Diagnosis: The MOKAECM Study, a Nationwide Experience. <i>PLoS ONE</i> , 2013, 8, e68945.	1.1	23

#	ARTICLE	IF	CITATIONS
235	Three Rounds of External Quality Assessment in France to Evaluate the Performance of 28 Platforms for Multiparametric Molecular Testing in Metastatic Colorectal and Non-Small Cell Lung Cancer. <i>Journal of Molecular Diagnostics</i> , 2016, 18, 205-214.	1.2	23
236	Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy. <i>Clinical Cancer Research</i> , 2018, 24, 4745-4753.	3.2	23
237	The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. <i>European Journal of Cancer</i> , 2019, 112, 1-8.	1.3	23
238	hENT1 Testing in Pancreatic Ductal Adenocarcinoma: Are We Ready? A Multimodal Evaluation of hENT1 Status. <i>Cancers</i> , 2019, 11, 1808.	1.7	23
239	Circulating Tumor DNA is Prognostic and Potentially Predictive of Eryaspase Efficacy in Second-line in Patients with Advanced Pancreatic Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 5208-5216.	3.2	23
240	HEPATITIS C VIRUS INFECTION IN PEDIATRIC LIVER TRANSPLANTATION. <i>Transplantation</i> , 1993, 55, 795-798.	0.5	22
241	Evidence of heterogeneity within colorectal liver metastases for allelic losses, mRNA level expression and <i>in vitro</i> response to chemotherapeutic agents. <i>International Journal of Cancer</i> , 2010, 127, 1028-1037.	2.3	22
242	Evaluation of predictive models in daily practice for the identification of patients with Lynch syndrome. <i>International Journal of Cancer</i> , 2012, 130, 1367-1377.	2.3	22
243	Intratumoral distribution of EGFR mutations and copy number in metastatic lung cancer, what impact on the initial molecular diagnosis?. <i>Journal of Translational Medicine</i> , 2014, 12, 131.	1.8	22
244	BRAF Mutation Status in Circulating Tumor DNA from Patients with Metastatic Colorectal Cancer: Extended Mutation Analysis from the AGE0 RASANC Study. <i>Cancers</i> , 2019, 11, 998.	1.7	22
245	Transcription of SST2 somatostatin receptor gene in human pancreatic cancer cells is altered by single nucleotide promoter polymorphism. <i>Gastroenterology</i> , 2001, 120, 200-209.	0.6	21
246	Mutation of TCF1 encoding hepatocyte nuclear factor 1 β in gynecological cancer. <i>Oncogene</i> , 2004, 23, 7588-7592.	2.6	21
247	Impact of GSTT1, GSTM1, GSTP1 and NAT2 genotypes on KRAS2 and TP53 gene mutations in colorectal cancer. <i>International Journal of Cancer</i> , 2004, 110, 183-187.	2.3	21
248	A Stepwise Integrated Approach to Personalized Risk Predictions in Stage III Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 1200-1212.	3.2	21
249	6-mercaptopurine promotes energetic failure in proliferating T cells. <i>Oncotarget</i> , 2017, 8, 43048-43060.	0.8	21
250	Thymidylate Synthase Promoter Polymorphism. <i>Journal of Clinical Oncology</i> , 2001, 19, 3442-3442.	0.8	20
251	UDP-glucuronosyltransferase UGT1A7 genetic polymorphisms in hepatocellular carcinoma: a differential impact according to seropositivity of HBV or HCV markers?. <i>BMC Cancer</i> , 2007, 7, 214.	1.1	20
252	Epidemiological study of prostate cancer (EPICAP): a population-based case-control study in France. <i>BMC Cancer</i> , 2014, 14, 106.	1.1	20

#	ARTICLE	IF	CITATIONS
253	Molecular patterns in deficient mismatch repair colorectal tumours: results from a French prospective multicentric biological and genetic study. <i>British Journal of Cancer</i> , 2014, 110, 2728-2737.	2.9	20
254	STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. <i>BMC Cancer</i> , 2015, 15, 496.	1.1	20
255	Mitochondrial D310 mutations in colorectal adenomas: An early but not causative genetic event during colorectal carcinogenesis. <i>International Journal of Cancer</i> , 2008, 122, 2242-2248.	2.3	19
256	Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i> -mutant ganglioglioma. <i>Neurology</i> , 2018, 91, 523-525.	1.5	19
257	Simultaneous detection of lung fusions using a multiplex RT-PCR next generation sequencing-based approach: a multi-institutional research study. <i>BMC Cancer</i> , 2018, 18, 828.	1.1	19
258	Can we classify ampullary tumours better? Clinical, pathological and molecular features. Results of an AGEO study. <i>British Journal of Cancer</i> , 2019, 120, 697-702.	2.9	19
259	No evidence for germline PTEN mutations in families with breast and brain tumours. <i>Journal of Clinical Oncology</i> , 1999, 17, 216-219.		18
260	The KRAS mutation detection within the initial management of patients with metastatic colorectal cancer: A status report in France in 2011. <i>European Journal of Cancer</i> , 2013, 49, 2126-2133.	1.3	18
261	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. <i>Gynecologic Oncology</i> , 2016, 141, 386-401.	0.6	18
262	Prognostic variables in low and high risk stage III colon cancers treated in two adjuvant chemotherapy trials. <i>European Journal of Cancer</i> , 2021, 144, 101-112.	1.3	18
263	Genetic characterization of the APC locus involved in familial adenomatous polyposis. <i>Gastroenterology</i> , 1991, 101, 154-160.	0.6	17
264	Association of a Duodenal Follicular Lymphoma and Hereditary Nonpolyposis Colorectal Cancer. <i>Modern Pathology</i> , 2000, 13, 586-590.	2.9	17
265	Delineation and candidate gene mutation screening of the 18q22 minimal region of deletion in head and neck squamous cell carcinoma. <i>Oncogene</i> , 2002, 21, 5016-5023.	2.6	17
266	9q31.2-rs865686 as a Susceptibility Locus for Estrogen Receptor-Positive Breast Cancer: Evidence from the Breast Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 1783-1791.	1.1	17
267	Clinical relevance of 8q23, 15q13 and 18q21 SNP genotyping to evaluate colorectal cancer risk. <i>European Journal of Human Genetics</i> , 2016, 24, 99-105.	1.4	17
268	Circadian genes and risk of prostate cancer: Findings from the EPICAP study. <i>International Journal of Cancer</i> , 2019, 145, 1745-1753.	2.3	17
269	Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. <i>Genetics in Medicine</i> , 2020, 22, 1533-1541.	1.1	17
270	Beyond KRAS status and response to anti-EGFR therapy in metastatic colorectal cancer. <i>Pharmacogenomics</i> , 2014, 15, 1043-1052.	0.6	16

#	ARTICLE	IF	CITATIONS
271	Why and how immunohistochemistry should now be used to screen for the <scp>BRAFV</scp>600E status in metastatic melanoma? The experience of a single institution (<scp>LCEP</scp>, Nice, France). Journal of the European Academy of Dermatology and Venereology, 2015, 29, 2436-2443.	1.3	16
272	Chemoresistant pleomorphic rhabdomyosarcoma: whole exome sequencing reveals underlying cancer predisposition and therapeutic options. Journal of Medical Genetics, 2020, 57, 104-108.	1.5	16
273	Circadian genes polymorphisms, night work and prostate cancer risk: Findings from the <scp>EPICAP</scp> study. International Journal of Cancer, 2020, 147, 3119-3129.	2.3	16
274	Usefulness of Plasma SARS-CoV-2 RNA Quantification by Droplet-based Digital PCR to Monitor Treatment Against COVID-19 in a B-cell Lymphoma Patient. Stem Cell Reviews and Reports, 2021, 17, 296-299.	1.7	16
275	High resolution genetic map of the adenomatous polyposis coli gene (APC) region. American Journal of Medical Genetics Part A, 1995, 56, 413-419.	2.4	15
276	Lessons from Tarceva in pancreatic cancer: where are we now, and how should future trials be designed in pancreatic cancer?. Current Opinion in Oncology, 2008, 20, 454-458.	1.1	15
277	Circulating Tumor DNA Measurement by Picoliter Droplet-Based Digital PCR and Vemurafenib Plasma Concentrations in Patients with Advanced BRAF-Mutated Melanoma. Targeted Oncology, 2017, 12, 365-371.	1.7	15
278	Urinary Angiogenin Reflects the Magnitude of Kidney Injury at the Infrahistologic Level. Journal of the American Society of Nephrology: JASN, 2017, 28, 678-690.	3.0	15
279	RAS mutation testing in patients with metastatic colorectal cancer in French clinical practice: A status report in 2014. Digestive and Liver Disease, 2018, 50, 507-512.	0.4	15
280	YAP/TAZ Signalling in Colorectal Cancer: Lessons from Consensus Molecular Subtypes. Cancers, 2020, 12, 3160.	1.7	15
281	The consensus Immunoscore in phase 3 clinical trials; potential impact on patient management decisions. OncoImmunology, 2020, 9, 1812221.	2.1	15
282	An atlas of inter- and intra-tumor heterogeneity of apoptosis competency in colorectal cancer tissue at single-cell resolution. Cell Death and Differentiation, 2022, 29, 806-817.	5.0	15
283	Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. British Journal of Cancer, 2022, 126, 440-448.	2.9	15
284	Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. Cancer Treatment Reviews, 2015, 41, 129-135.	3.4	14
285	Phase III randomized trial comparing 5-fluorouracil and oxaliplatin with or without docetaxel in first-line advanced gastric cancer chemotherapy (GASTFOX study). Digestive and Liver Disease, 2018, 50, 408-410.	0.4	14
286	Role of circulating tumor DNA in the management of patients with colorectal cancer. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 396-402.	0.7	14
287	<i>NF1</i> mutations identify molecular and clinical subtypes of lung adenocarcinomas. Cancer Medicine, 2019, 8, 4330-4337.	1.3	14
288	Association of breast cancer risk with polymorphisms in genes involved in the metabolism of xenobiotics and interaction with tobacco smoking: A geneâ€set analysis. International Journal of Cancer, 2019, 144, 1896-1908.	2.3	14

#	ARTICLE	IF	CITATIONS
289	Avelumab versus standard second line treatment chemotherapy in metastatic colorectal cancer patients with microsatellite instability: The SAMCO-PRODIGE 54 randomised phase II trial. <i>Digestive and Liver Disease</i> , 2021, 53, 318-323.	0.4	14
290	PCR-Based Genotyping Can Generate Artifacts in LOH Analyses. <i>BioTechniques</i> , 1999, 27, 1100-1102.	0.8	13
291	An alternative to prophylactic colectomy for colon cancer prevention in HNPCC syndrome. <i>Gut</i> , 2005, 54, 169-169.	6.1	13
292	No somatic genetic change in the paxillin gene in nonsmallâ€cell lung cancer. <i>Molecular Carcinogenesis</i> , 2009, 48, 581-585.	1.3	13
293	Predictive Modeling of Tacrolimus Dose Requirement Based on High-Throughput Genetic Screening. <i>American Journal of Transplantation</i> , 2017, 17, 1008-1019.	2.6	13
294	Predictive molecular pathology in nonâ€small cell lung cancer in France: The past, the present and the perspectives. <i>Cancer Cytopathology</i> , 2020, 128, 601-610.	1.4	13
295	Evaluation of miR 31 3p as a biomarker of prognosis and panitumumab benefit in <i>RAS</i>-wt advanced colorectal cancer (aCRC): Analysis of patients (pts) from the PICCOLO trial.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3547-3547.	0.8	13
296	Epidemiology, Risk Factors and Diagnosis of Small Bowel Adenocarcinoma. <i>Cancers</i> , 2022, 14, 2268.	1.7	13
297	Is the gene encoding Chibby implicated as a tumour suppressor in colorectal cancer ?. <i>BMC Cancer</i> , 2004, 4, 31.	1.1	12
298	Preclinical assessment of cisplatin-based therapy versus docetaxel-based therapy on a panel of human non-small-cell lung cancer xenografts. <i>Anti-Cancer Drugs</i> , 2009, 20, 932-940.	0.7	12
299	A comprehensive characterization of the impact of mycophenolic acid on the metabolism of Jurkat T cells. <i>Scientific Reports</i> , 2017, 7, 10550.	1.6	12
300	Partnering with patients in translational oncology research: ethical approach. <i>Journal of Translational Medicine</i> , 2017, 15, 74.	1.8	12
301	Increased expression of the thyroid hormone nuclear receptor TR β 1 characterizes intestinal tumors with high Wnt activity. <i>Oncotarget</i> , 2018, 9, 30979-30996.	0.8	12
302	Stratification of chemotherapy-treated stage III colorectal cancer patients using multiplexed imaging and single-cell analysis of T-cell populations. <i>Modern Pathology</i> , 2022, 35, 564-576.	2.9	12
303	Improvement of the quality of BRAF testing in melanomas with nationwide external quality assessment, for the BRAF EQA group. <i>BMC Cancer</i> , 2013, 13, 472.	1.1	11
304	Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy. <i>Pharmacogenomics Journal</i> , 2014, 14, 135-141.	0.9	11
305	Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers. <i>British Journal of Cancer</i> , 2015, 113, 680-685.	2.9	11
306	Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 9q22.33 and 14q13.3 detects novel candidate functional SNPs in Europeans from metropolitan France and Melanesians from New Caledonia. <i>International Journal of Cancer</i> , 2016, 139, 617-627.	2.3	11

#	ARTICLE	IF	CITATIONS
307	Impact of single nucleotide polymorphisms in DNA repair pathway genes on response to chemoradiotherapy in rectal cancer patients: Results from ACCORD12/PRODIGE2 phase III trial. <i>International Journal of Cancer</i> , 2019, 145, 3163-3172.	2.3	11
308	Prognostic value of the PrP ^C -ILK-IDO1 axis in the mesenchymal colorectal cancer subtype. <i>Oncolmmunology</i> , 2021, 10, 1940674.	2.1	11
309	Multiethnic genome-wide association study of differentiated thyroid cancer in the EPITHYR consortium. <i>International Journal of Cancer</i> , 2021, 148, 2935-2946.	2.3	11
310	The Cellular Prion Protein and the Hallmarks of Cancer. <i>Cancers</i> , 2021, 13, 5032.	1.7	11
311	Clinical assessment of the miR-34, miR-200, ZEB1 and SNAIL EMT regulation hub underlines the differential prognostic value of EMT miRs to drive mesenchymal transition and prognosis in resected NSCLC. <i>British Journal of Cancer</i> , 2021, 125, 1544-1551.	2.9	11
312	Indeterminate third-generation recombinant immunoblot assay in hepatitis C virus infection. <i>Journal of Hepatology</i> , 1994, 21, 133-134.	1.8	10
313	Down-regulation of the phosphoenolpyruvate carboxykinase gene in human colon tumors and induction by omega-3 fatty acids. <i>Biochimie</i> , 2010, 92, 1772-1777.	1.3	10
314	PRODIGE 59-DURIGAST trial: A randomised phase II study evaluating FOLFIRI + Durvalumab ± Tremelimumab in second-line of patients with advanced gastric cancer. <i>Digestive and Liver Disease</i> , 2021, 53, 420-426.	0.4	10
315	Analysis of sera indeterminate by Ortho-HCV RIBA-2 by using three confirmatory assays for anti-hepatitis C virus antibody. <i>Journal of Clinical Microbiology</i> , 1994, 32, 2071-2075.	1.8	10
316	Genetic alterations in hepatocellular adenomas. <i>Hepatology</i> , 2003, 37, 480-480.	3.6	9
317	Plasma circulating tumor DNA in pancreatic adenocarcinoma for screening, diagnosis, prognosis, treatment and follow-up: A systematic review. <i>Cancer Treatment Reviews</i> , 2020, 87, 102028.	3.4	9
318	Everolimus and plicamycin specifically target chemoresistant colorectal cancer cells of the CMS4 subtype. <i>Cell Death and Disease</i> , 2021, 12, 978.	2.7	9
319	Molecular profiling of advanced soft-tissue sarcomas: the MULTISARC randomized trial. <i>BMC Cancer</i> , 2021, 21, 1180.	1.1	9
320	Dual Blockade of Epidermal Growth Factor Receptor-Induced Pathways: A New Avenue to Treat Metastatic Colorectal Cancer. <i>Journal of Clinical Oncology</i> , 2012, 30, 1550-1552.	0.8	8
321	Women Epidemiology Lung Cancer (WELCA) study: reproductive, hormonal, occupational risk factors and biobank. <i>BMC Public Health</i> , 2017, 17, 324.	1.2	8
322	Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives. <i>Cancers</i> , 2021, 13, 4743.	1.7	8
323	Lipase amylase ratio in acute pancreatitis. <i>European Journal of Gastroenterology and Hepatology</i> , 1993, 5, 361-366.	0.8	7
324	Hepatocellular Carcinoma and Occupation in Men: A Case-Control Study. <i>Journal of Occupational and Environmental Medicine</i> , 2008, 50, 212-220.	0.9	7

#	ARTICLE	IF	CITATIONS
325	Evaluation and Validation of Diagnostic Tests for Guiding Therapeutic Decisions. <i>Therapie</i> , 2009, 64, 195-201.	0.6	7
326	Unresectable metastatic colorectal cancer patient cured with cetuximab-based chemotherapy: a case report with new molecular insights. <i>Journal of Gastrointestinal Oncology</i> , 2018, 9, E23-E27.	0.6	7
327	Successful Targeting of an ATG7-RAF1 Gene Fusion in Anaplastic Pleomorphic Xanthoastrocytoma With Leptomeningeal Dissemination. <i>JCO Precision Oncology</i> , 2019, 3, 1-7.	1.5	7
328	Facing new challenges to informed consent processes in the context of translational research: the case in CARPEM consortium. <i>BMC Medical Ethics</i> , 2021, 22, 21.	1.0	7
329	Gene network and biological pathways associated with susceptibility to differentiated thyroid carcinoma. <i>Scientific Reports</i> , 2021, 11, 8932.	1.6	7
330	Risk of lung cancer among women in relation to lifetime history of tobacco smoking: a population-based case-control study in France (the WELCA study). <i>BMC Cancer</i> , 2021, 21, 711.	1.1	7
331	Highly Specific Droplet-Digital PCR Detection of Universally Methylated Circulating Tumor DNA in Endometrial Carcinoma. <i>Clinical Chemistry</i> , 2022, 68, 782-793.	1.5	7
332	Detection by DGGE of a new polymorphism closely linked to the adenomatous polyposis coli region. <i>Human Genetics</i> , 1992, 88, 658-660.	1.8	6
333	Chromosome 12 alterations and c-Ki-ras mutations in colorectal tumors. <i>Cancer Genetics and Cytogenetics</i> , 1993, 69, 161-162.	1.0	6
334	Fatal reactivation of hepatitis B virus mutant following cytotoxic treatment. <i>Journal of Hepatology</i> , 1994, 21, 1152.	1.8	6
335	O-0028 Adjuvant Folfox4 +/- Cetuximab in KRAS Wild-Type Patients with Resected Stage III Colon Cancer Results from the Petacc8 Intergroup Trial. <i>Annals of Oncology</i> , 2012, 23, iv17.	0.6	6
336	DeltaN TP63 reactivation, epithelial phenotype maintenance, and survival in lung squamous cell carcinoma. <i>Tumor Biology</i> , 2012, 33, 41-51.	0.8	6
337	A major genetic accelerator of cancer diagnosis: rs867228 in FPR1. <i>Oncolmmunology</i> , 2021, 10, 1859064.	2.1	6
338	Fine-mapping of two differentiated thyroid carcinoma susceptibility loci at 2q35 and 8p12 in Europeans, Melanesians and Polynesians. <i>Oncotarget</i> , 2021, 12, 493-506.	0.8	6
339	Prognostic value of BRAF V600E and KRAS exon 2 mutations in microsatellite stable (MSS), stage III colon cancers (CC) from patients (pts) treated with adjuvant FOLFOX+/- cetuximab: A pooled analysis of 3934 pts from the PETACC8 and N0147 trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3507-3507.	0.8	6
340	Reliability of presymptomatic test for adenomatous polyposis coli. <i>Lancet</i> , The, 1991, 337, 1171-1172.	6.3	5
341	Prevalence of anti-hepatitis C virus antibodies among patients with alcoholic liver disease, supplemented by 4-RIBA. <i>Digestive Diseases and Sciences</i> , 1992, 37, 156-157.	1.1	5
342	Prevalence of hepatitis C virus RNA in suspected drug induced liver diseases. <i>Journal of Hepatology</i> , 1993, 19, 487-489.	1.8	5

#	ARTICLE	IF	CITATIONS
343	Effect of chemoprevention by low-dose aspirin of new or recurrent colorectal adenomas in patients with Lynch syndrome (AAS-Lynch): study protocol for a multicenter, double-blind, placebo-controlled randomized controlled trial. <i>Trials</i> , 2020, 21, 764.	0.7	5
344	Circulating tumor DNA in advanced non-small-cell lung cancer patients with HIV is associated with shorter overall survival: Results from a Phase II trial (IFCT-1001 CHIVA). <i>Lung Cancer</i> , 2021, 157, 124-130.	0.9	5
345	Pembrolizumab with Capox Bevacizumab in patients with microsatellite stable metastatic colorectal cancer and a high immune infiltrate: The FFCD 1703-POCHI trial. <i>Digestive and Liver Disease</i> , 2021, 53, 1254-1259.	0.4	5
346	Development and validation of a RNAseq signature for prognostic stratification in endometrial cancer. <i>Gynecologic Oncology</i> , 2022, , .	0.6	5
347	Host and viral characteristics affecting the response to interferon therapy in chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , 1995, 7, 335-40.	0.8	5
348	Frequent polymorphism in the 13th exon of the adenomatous polyposis coli gene. <i>Human Genetics</i> , 1992, 90, 161-3.	1.8	4
349	Association of serum antibodies against p53 protein with poor survival in patients with Zollingerâ€“Ellison syndrome. <i>Gastroenterology</i> , 1998, 114, 37-43.	0.6	4
350	Beyond the KRAS test. <i>European Journal of Cancer</i> , 2009, 45, 398-399.	1.3	4
351	Reply to D. Santini et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e208-e209.	0.8	4
352	Colon Cancer Mutation: Prognosis/Predictionâ€“Letter. <i>Clinical Cancer Research</i> , 2013, 19, 1300-1300.	3.2	4
353	A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the Clinic. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-17.	1.0	4
354	DNAsheII Protects DNA Stored at Room Temperature for Downstream Next-Generation Sequencing Studies. <i>Biopreservation and Biobanking</i> , 2019, 17, 352-354.	0.5	4
355	Clinical Outcomes in Patients With Colon Cancer With Microsatellite Instability of Sporadic or Familial Origin Treated With Adjuvant FOLFOX With or Without Cetuximab: A Pooled Analysis of the PETACC8 and N0147 Trials. <i>JCO Precision Oncology</i> , 2020, 4, 116-127.	1.5	4
356	The area between ROC curves, a nonâ€“parametric method to evaluate a biomarker for patient treatment selection. <i>Biometrical Journal</i> , 2020, 62, 1476-1493.	0.6	4
357	Deciphering the Role of Intestinal Crypt Cell Populations in Resistance to Chemotherapy. <i>Cancer Research</i> , 2021, 81, 2730-2744.	0.4	4
358	Practices and expectations on the use of circulating tumor DNA in colorectal cancer patients: A bi-national AGEO/AIOM/GERCOR/FFCD/FRENCH survey. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101681.	0.7	4
359	Overexpression of p53: A rare event in a large series of white patients with hepatocellular carcinoma. <i>Hepatology</i> , 1992, 16, 1171-1175.	3.6	4
360	Abstract 3575: The OncoNetwork Consortium: A global collaborative research study on the development and verification of an Ion AmpliSeq RNA gene lung fusion panel. <i>Cancer Research</i> , 2014, 74, 3575-3575.	0.4	4

#	ARTICLE	IF	CITATIONS
361	Improving access to molecularly defined clinical trials for patients with colorectal cancer: The EORTC SPECTAcOLOR platform.. <i>Journal of Clinical Oncology</i> , 2015, 33, 575-575.	0.8	4
362	Next-Generation Sequencing Targeted Panel in Routine Care for Metastatic Colon Cancers. <i>Cancers</i> , 2021, 13, 5750.	1.7	4
363	Circulating tumor DNA: a help to guide therapeutic strategy in patients with borderline and locally advanced pancreatic adenocarcinoma?. <i>Digestive and Liver Disease</i> , 2022, 54, 1428-1436.	0.4	4
364	Comment on "KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer". <i>British Journal of Cancer</i> , 2014, 111, 2379-2380.	2.9	3
365	Frequent intragenic rearrangements of DPYD in colorectal tumours. <i>Pharmacogenomics Journal</i> , 2015, 15, 211-218.	0.9	3
366	Biochemically Tracked Variability of Blood Plasma Thawed-State Exposure Times in a Multisite Collection Study. <i>Biopreservation and Biobanking</i> , 2020, 18, 376-388.	0.5	3
367	Characterization of Plasma Cell-Free DNA Integrity Using Droplet-Based Digital PCR: Toward the Development of Circulating Tumor DNA-Dedicated Assays. <i>Frontiers in Oncology</i> , 2021, 11, 639675.	1.3	3
368	Prognostic Relevance of Pancreatic Adenocarcinoma Whole-Tumor Transcriptomic Subtypes and Components. <i>Clinical Cancer Research</i> , 2021, 27, 6491-6499.	3.2	3
369	Mir-31-3p as a predictive biomarker of cetuximab effects in a post hoc analysis of new EPOC phase III trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3523-3523.	0.8	3
370	MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, TPS3632-TPS3632.	0.8	3
371	Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4136-4136.	0.8	3
372	Role of GSTM1 and GSTT1 genotypes in differentiated thyroid cancer and interaction with lifestyle factors: Results from case-control studies in France and New Caledonia. <i>PLoS ONE</i> , 2020, 15, e0228187.	1.1	3
373	Microsatellite instability analysis for the screening of synchronous endometrial and ovarian cancer in Lynch syndrome. <i>Anticancer Research</i> , 2013, 33, 3977-81.	0.5	3
374	Circulating Ubiquitous RNA, A Highly Predictive and Prognostic Biomarker in Hospitalized Coronavirus Disease 2019 (COVID-19) Patients. <i>Clinical Infectious Diseases</i> , 2021, , .	2.9	3
375	Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers. <i>British Journal of Cancer</i> , 2022, 127, 1123-1132.	2.9	3
376	Analysis of Candidate Genes in Occurrence and Growth of Colorectal Adenomas. <i>Journal of Oncology</i> , 2009, 2009, 1-9.	0.6	2
377	Incidence of KRAS status in ongoing adjuvant trials in colon cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 171-178.	1.0	2
378	Toward an individualizing therapy for colorectal cancer: the example of the anti-EGFR monoclonal antibodies. <i>Personalized Medicine</i> , 2009, 6, 145-157.	0.8	2

#	ARTICLE	IF	CITATIONS
379	Microsatellite Status and Adjuvant Chemotherapy in Patients with Stage II Colon Cancer. <i>Current Colorectal Cancer Reports</i> , 2010, 6, 148-157.	1.0	2
380	Microsatellite instability analysis in uterine cavity washings as a screening tool for endometrial cancer in Lynch syndrome. <i>Familial Cancer</i> , 2011, 10, 655-657.	0.9	2
381	Mutational Diversity of Lung Cancer and Associated Lymph Nodes. An Exploratory Prospective Study of 4 Resected cIIIA-N2. <i>Pathology and Oncology Research</i> , 2019, 25, 319-325.	0.9	2
382	Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI)-PRODIGE 62: A multicentre, randomised, non-comparative phase II study. <i>Digestive and Liver Disease</i> , 2020, 52, 347-350.	0.4	2
383	Effectiveness of a dedicated small bowel neoplasia screening program by capsule endoscopy in Lynch syndrome: 5 years results from a tertiary care center. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482093431.	1.4	2
384	Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAIN - PRODIGE 71 - (FFCD 1710) phase III study. <i>Digestive and Liver Disease</i> , 2020, 52, 1143-1147.	0.4	2
385	Role of DNA Repair Variants and Diagnostic Radiology Exams in Differentiated Thyroid Cancer Risk: A Pooled Analysis of Two Caseâ€“Control Studies. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1208-1217.	1.1	2
386	Biomarker-driven access to crizotinib in ALK-, MET-, or ROS1-positive malignancies in adults and children: Feasibility of the French National AcsÂ© Program.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS2647-TPS2647.	0.8	2
387	Analysis of DNA mismatch repair (MMR) and clinical outcome in stage III colon cancers from patients (pts) treated with adjuvant FOLFOX +/- cetuximab in the PETACC8 and NCCTG N0147 adjuvant trials.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3506-3506.	0.8	2
388	Molecular predictors of response to EGFR antibodies in colorectal cancer. <i>Current Colorectal Cancer Reports</i> , 2009, 5, 57-63.	1.0	1
389	Reply to S.D. Richman et al. <i>Journal of Clinical Oncology</i> , 2011, 29, e356-e357.	0.8	1
390	Prediction of response to anticancer treatment as simple as the resolution of ordinary differential equations?. <i>Gut</i> , 2012, 61, 637-638.	6.1	1
391	Therapeutic implications of DNA mismatch repair in adjuvant colorectal cancer chemotherapy. <i>Colorectal Cancer</i> , 2013, 2, 51-59.	0.8	1
392	Cetuximabâ€”an option for unresectable CRC liver metastases. <i>Nature Reviews Clinical Oncology</i> , 2013, 10, 374-375.	12.5	1
393	ERBB3-Activating Mutations in Small Bowel Adenocarcinomas. <i>JCO Precision Oncology</i> , 2018, 2, 1-9.	1.5	1
394	Frequent allelic loss at chromosome 3p distinct from genetic alterations of the 8-oxoguanine DNA glycosylase 1 gene in head and neck cancer. , 1999, 26, 254.		1
395	Abstract 2820: Clinical significance of low frequency KRAS and BRAF subclones for advanced colon cancer management. , 2014, , .		1
396	Hsa-miR-31-3p expression in FFPE tumor samples as a predictor of anti-EGFR response in patients with metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2013, 31, 3562-3562.	0.8	1

#	ARTICLE	IF	CITATIONS
397	Mutations du gène APC et instabilité chromosomique.. Medecine/Sciences, 2001, 17, 954.	0.0	1
398	Gender specific profiling in SCN1A polymorphisms and time to recurrence in patients with stage II/III colorectal cancer.. Journal of Clinical Oncology, 2013, 31, 393-393.	0.8	1
399	337...Pembrolizumab in combination with xelox bevacizumab in patients with microsatellite stable (MSS) metastatic colorectal cancer and a high immune infiltrate: a proof of concept study. FFCO 1703 POCHI. , 2020, , .		1
400	BRCA1 and RAD51C promotor methylation in human resectable pancreatic adenocarcinoma. Clinics and Research in Hepatology and Gastroenterology, 2022, 46, 101880.	0.7	1
401	Transcription of sst2 somatostatin receptor gene is altered by promoter polymorphidism in human pancreatic cancer cells. Gastroenterology, 2000, 118, A711.	0.6	0
402	TCF1/HNF1 mutations in hepatocellular adenoma. Journal of Hepatology, 2003, 38, 22.	1.8	0
403	Molecular predictors of response to EGFR antibodies in colorectal cancer. Current Colorectal Cancer Reports, 2008, 4, 119-125.	1.0	0
404	Potential Role of KRAS and Other Mutations in the Adjuvant Therapy of Colorectal Cancer. Current Colorectal Cancer Reports, 2012, 8, 192-203.	1.0	0
405	Predictive Value of LKB1 in Patients with Resected Non Small Cell Lung Cancer. Annals of Oncology, 2012, 23, ix77.	0.6	0
406	Prediction of Chemotherapy Toxicities. , 2013, , 249-273.		0
407	hENT1 testing in pancreatic ductal adenocarcinoma: Are we ready yet? A multimodal evaluation of hENT1 status. Pancreatology, 2016, 16, S89.	0.5	0
408	Women at a Disadvantage in Fluorouracil Treatmentâ€”Reply. JAMA Oncology, 2016, 2, 830.	3.4	0
409	Are There Biochemical and Molecular Biological Factors to Distinguish the Rectal Cancer by the Colon Cancer?. , 2018, , 503-507.		0
410	Towards a RAS mutation status in a single day for patients with advanced colorectal cancers. Authorsâ€™ reply. Digestive and Liver Disease, 2018, 50, 974-975.	0.4	0
411	Clinicopathologic characteristics of endometrial cancer in Lynch syndrome.. Journal of Clinical Oncology, 2012, 30, 5098-5098.	0.8	0
412	Abstract 141: Nonsteroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase-2 polymorphisms, and breast cancer risk.. , 2013, , .		0
413	ERBB2 gene as a potential therapeutic target in small bowel adenocarcinoma.. Journal of Clinical Oncology, 2014, 32, 205-205.	0.8	0
414	Prognostic value of KRAS exon 2 gene mutations in stage III colon cancer: Post hoc analyses of the PETACC8 trial.. Journal of Clinical Oncology, 2014, 32, 3549-3549.	0.8	0

#	ARTICLE	IF	CITATIONS
415	Association between c-Met expression, miR-31-3p expression and progression free survival in the New EPOC study.. Journal of Clinical Oncology, 2015, 33, 3545-3545.	0.8	0
416	DYPD genotyping to predict toxicity in patients with stage III colon cancer treated with 5-fluorouracil-based adjuvant chemotherapy in the PETACC-8 phase III trial.. Journal of Clinical Oncology, 2015, 33, 3584-3584.	0.8	0
417	Proof of Principle for Mutations Monitoring Using Picoliter-Droplet Digital PCR on DNA and Living Cells: Application to Myelodysplastic Syndromes. Blood, 2016, 128, 5515-5515.	0.6	0
418	Ampullary carcinoma prognostic markers. Oncotarget, 2019, 10, 4509-4510.	0.8	0
419	Translational epigenetics in precision medicine of colorectal cancer. , 2022, , 19-41.		0
420	Microsatellite instability analysis in uterine cavity washings to detect endometrial cancer in Lynch syndrome. Anticancer Research, 2014, 34, 3211-5.	0.5	0